| Update in primary aldosteronism. | |
| | |
MedLine Citation:
|
PMID: 19737921 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
It is now widely recognized that primary aldosteronism (PA) is much more common than previously thought, accounting for up to 5-10% of hypertensives, and that aldosterone excess has adverse cardiovascular consequences that go above and beyond hypertension development. These findings have precipitated a marked resurgence of research activity, most of which has supported the concept that PA plays an important role in cardiovascular disease states and should be systematically sought and specifically treated, and the development of an Endocrine Society clinical guideline for the case detection, diagnosis, and management of this common, specifically treatable, and potentially curable condition. Areas of recent, topical research include: 1) the demonstration of excess morbidity in patients with PA compared with other forms of hypertension, confirming the clinical relevance of non-blood pressure-dependent adverse effects of aldosterone excess; 2) the further demonstration that this excess morbidity and mortality are ameliorated with specific (but not nonspecific antihypertensive) therapy directed against aldosterone excess, confirming the importance of detection and diagnosis of PA to enable optimal specific management; 3) the development of new treatment strategies; 4) an ongoing appraisal and refinement of diagnostic approaches including screening, subtype differentiation, and new assay development; and 5) further insights into the importance and nature of genetic factors related to the development of PA. |
| | |
Authors:
|
Michael Stowasser |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't Date: 2009-09-08 |
Journal Detail:
|
Title: The Journal of clinical endocrinology and metabolism Volume: 94 ISSN: 1945-7197 ISO Abbreviation: J. Clin. Endocrinol. Metab. Publication Date: 2009 Oct |
Date Detail:
|
Created Date: 2009-10-07 Completed Date: 2009-10-20 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0375362 Medline TA: J Clin Endocrinol Metab Country: United States |
Other Details:
|
Languages: eng Pagination: 3623-30 Citation Subset: AIM; IM |
Affiliation:
|
Hypertension Unit, University of Queensland School of Medicine, Princess Alexandra Hospital, Woolloongabba Brisbane 4102, Australia. m.stowasser@uq.edu.au |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adrenalectomy* Adrenocorticotropic Hormone / blood Aldosterone / blood* Aldosterone Antagonists / administration & dosage, therapeutic use* Aldosterone Synthase / antagonists & inhibitors Amiloride / therapeutic use Antihypertensive Agents / therapeutic use Chromosomes, Human, Pair 7 Diagnosis, Differential Drug Administration Schedule Glucocorticoids / therapeutic use Humans Hyperaldosteronism* / complications, diagnosis, genetics, therapy Hypertension / blood, drug therapy, etiology* Linkage (Genetics) Lod Score Spironolactone / analogs & derivatives, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Aldosterone Antagonists; 0/Antihypertensive Agents; 0/Glucocorticoids; 0/eplerenone; 2609-46-3/Amiloride; 52-01-7/Spironolactone; 52-39-1/Aldosterone; 9002-60-2/Adrenocorticotropic Hormone; EC 1.14.15.4/Aldosterone Synthase |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Thyroid hormone therapy for obesity and nonthyroidal illnesses: a systematic review.
Next Document: Low-birth weight children develop lower sex hormone binding globulin and higher dehydroepiandrostero...